UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. | --- | --- | |---------------------------------------------------------------|-----------------------------| | (Exact Name of Reg ...

LEARSI BIOMED Corporate Presentation March 2022 t 12222 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forwardlooking statements c ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2021 Results Conference Call March 10, 2022 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - Chief Executive Officer Dr. Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Wedbush Zegbeh Jallah - ROTH Capital Partners Rohit Basin - Needham Jon Wolleben - JMP Securities Operator Good day. Thank you for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to __________ | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------- ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Yi Chen - H.C. Wainwright Andreas Argyrides - Wedbush Jon Wolleben - JMP Securities Zegbeh Jallah - ROTH Capital Partners Operator Good day. Thank you ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Large accelerated filer ☐ Accelerated filer ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Securities registered pur ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Annabel Samimy - Stifel Andreas Argyrides - Wedbush Securities Yi Chen - H.C. Wainwright Jon Wolleben - JMP Securities Serge Belanger - Ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | |---------------------------------------------------------------------------------|----------------------------------------| | Clearside Biomedi ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Jenny Kobin - Head of Investor Relations George Lasezkay - President, Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners, LLC Annabel Samimy - Stifel, Nicolaus & Company, Inc. Andreas Argyrides - Wedbush Securities Inc. Serge Belanger - Needha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State or other jurisdiction ...